Tom Cancro: Yes. So, roughly $9 million increase in EBITDA, and how do we get there, is your question. Well, at the midpoint of revenue guidance, you’re doing about 49 million more than the prior year. As we said earlier, we expect margins, gross margins, adjusted gross margins to be flat to the fourth quarter of 2022. That yields about 12 million in gross profit. And 9 of that falls to EBITDA. So, what that tells you is, we’re getting much more operating leverage. We’ve been able to hold SG&A costs relatively flat, not entirely flat because we do have 20% revenue growth. We’re going to have some incremental cost, but largely flat because of some of the savings we talked about previously as a result of sharpening our focus to our remaining business.
Unidentified Analyst: Thanks. Appreciate the detail there. With respect to top line visibility, I guess, one, how much of this incremental sales guide, close to 50 million year-over-year at the midpoint is based on contracted revenue versus is assumed ? And two, any additional color on what might drive the target either to the low-end or high-end of the guidance range? Thank you.
Brian Adams: I’ll start Jack and just provide a little bit of color. As I was mentioning before, the backlog is extremely healthy right now and continues to grow. And I think that all that we are observing through conversations with customers. What we’re hearing through the National PACE Association is that we would expect to see an acceleration of growth over the next few years. The revenue that we’re projecting we feel very reasonable for what we’re seeing happen in the market right now, but I’ll let Tom talk a little bit more about the specifics.
Tom Cancro: Yes. Jack, at the high-end of the range, the growth resembles 2022 or the split of the growth that is to say a little more than half of it comes from same store sales, if you will, new participants at existing centers. And the rest is split between new centers and pricing, drug price increases, new contracts, etcetera. At the low-end of the range, it is almost entirely existing centers and pricing and very little ascribed to new sectors added.
Unidentified Analyst: Great. Thank you.
Operator: Thank you. I’m showing no further questions at this time. Thank you for participating. This concludes today’s conference call. You may now disconnect. And I’m sorry, it looks like we have one question that just popped in from Jessica Tassan with Piper Sandler. Your line is now open.
Jessica Tassan: Sorry about that. So, can you just remind us what the backlog to revenue conversion process looks like? Like how many years of projected revenue are included in backlog and what is the anticipated rate of conversion?
Brian Adams: Thanks, Jessica. Good question. Good to talk to you. So, those are all contracts that are in place today. What’s reflected in backlog is at full ramp. So, once those contracts are at maturity and those locations are, they have full census associated with them, which on average is about 250 participants or 250 members. So, we would expect over time and that time is anywhere between 18 months to three years. We would see that revenue be realized. Effectively what you’re looking at there in our backlog is ARR, right. That’s what we’re quoting. So, it does take some time for those locations to ramp though.
Jessica Tassan: Got it. That makes sense. And then just Brian, you spent a little bit of time in the prepared remarks talking about the drug interaction or the MedWise platform. Just interested, what is the monetization strategy for that platform right now? And then is the intention to sell this product or this platform outside of PACE? And kind of where does that fit within the landscape of physician drug reference products? Our understanding is has about 50% of market share. And so just curious to know if you think about MedWise as a complement or an alternative to that offering?
